Followers | 27 |
Posts | 3920 |
Boards Moderated | 0 |
Alias Born | 01/02/2003 |
Wednesday, August 15, 2012 9:09:07 AM
New therapy prevents lung cancer growth in mice
By smspaz3 · Yesterday at 10:20 am · 2 replies
In Non-small cell lung cancer - Stage IV
Recommend Follow replies Problem More options
Shared with the public
http://feedproxy.google.com/~r/sciencedaily/health_medicine/lung_cancer/~3/ TRwv8OosVsE/120813130625.htm?utm_source=feedburner&utm_medium=email
Explore topics in this post
2 replies Reply
Oldest firstNewest first
By gpawelski
Reply 3290276
Yesterday at 12:59 pm
Report post
Thanks for this!
Cancer stem cells (CSCs), are aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated via a pathway that mirrors normal stem cell development. Disrupting the pathway, researchers are able to halt expansion of CSCs.
One approach is to force the CSCs into a differentiated state, thereby impairing stem characteristics, such as self-renewal. Interference with the Notch, Wnt, or Hedgehog pathways that are thought to regulate differentiation, are strategies that have been proposed.
Erivedge (vismodegib) is one such drug that inhibits Hedgehog signaling by targeting the serpentine receptor Smoothened (SMO), and has produced promising anti-tumor responses in clinical studies of cancers driven by mutations in this pathway.
Breast cancer represents a benchmark for studying the influence of Notch pathways on CSCs. A significant reduction of mammosphere-forming effeciency has been achieved with gamma-secretase inhibitor (GSI). Since a similar effect was seen with the EGFR tyrosine kinase inhibitor gefitinib, it is conceivable that the dual inhibition of Notch and EGFR may exert a synergistic effect on lung cancer.
And a number of Wnt modulators or inhibitors have been identified like COX-2 inhibitors (celecoxib and rofecoxib). The Wnt activity identifies the colon CSC population.
The capacity to study human tumor microenvironments enables the functional profiling platform to conduct discovery work on the most sophisticated classes of compounds that influence cell signaling at the level of Notch, Hedgehog and Wnt, among others (Gonsalves, F, et al. 2011).
http://www.inspire.com/groups/lung-cancer-survivors/discussion/new-therapy-prevents-lung-cancer-growth-in-mice/
Recent CRIS News
- Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 • PR Newswire (US) • 11/07/2024 01:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/01/2024 08:35:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/30/2024 10:27:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 01:59:04 AM
- Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement • PR Newswire (US) • 10/29/2024 10:04:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 10/29/2024 01:50:30 AM
- Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer • PR Newswire (US) • 09/23/2024 12:30:00 PM
- Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference • PR Newswire (US) • 09/17/2024 11:30:00 AM
- Curis to Present at Upcoming Healthcare Conferences in September • PR Newswire (US) • 09/04/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 12:08:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:05:25 PM
- Curis Provides Second Quarter 2024 Financial and Operating Update • PR Newswire (US) • 08/01/2024 12:00:00 PM
- Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- Curis to Present at Upcoming Healthcare Conference in July • PR Newswire (US) • 07/10/2024 11:30:00 AM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/08/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/14/2024 08:03:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:12:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:11:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:09:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:32 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM